Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
decisions by regulatory authorities impacting labeling, manufacturing processes, safety, and/or other matters that could affect the availability or commercial potential of Pfizers oral GIPR antagonist candidate, other earlier obesity programs or any such other product candidates
Muhlemann MF, Carter GO, Cream JJ, Wise P
Multiple factors will make more people engage and stick to using the drugs: Pills : as many users are repelled by the need to inject themselves regularly, the emergence of a pill alternative could boost sales and retention
Pharmacol Rev
US$ 21.64
US$ 21.52
US$ 25.73
US$ 28.96
US$ 24.45
US$ 24.51
US$ 21.99
US$ 22.12
US$ 23.84
